EA201500552A1 - Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью - Google Patents

Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью

Info

Publication number
EA201500552A1
EA201500552A1 EA201500552A EA201500552A EA201500552A1 EA 201500552 A1 EA201500552 A1 EA 201500552A1 EA 201500552 A EA201500552 A EA 201500552A EA 201500552 A EA201500552 A EA 201500552A EA 201500552 A1 EA201500552 A1 EA 201500552A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
acute
relaxin
acute health
insufficiency
Prior art date
Application number
EA201500552A
Other languages
English (en)
Inventor
Элейн Унмори
Сэм Л. Тейчман
Гад Коттер
Деннис Р. Стьюарт
Марта Джо Вайтхаус
Original Assignee
Кортера, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кортера, Инк. filed Critical Кортера, Инк.
Publication of EA201500552A1 publication Critical patent/EA201500552A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

В заявке описаны способы снижения декомпенсации посредством острого вмешательства у индивидуумов, страдающих острой декомпенсированной сердечной недостаточностью. В частности, в заявке описаны способы лечения острой декомпенсации сердца путем введения релаксина в фармацевтически эффективном количестве.
EA201500552A 2008-05-16 2009-05-15 Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью EA201500552A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12788908P 2008-05-16 2008-05-16
US19054508P 2008-08-28 2008-08-28
US20124008P 2008-12-08 2008-12-08
US16433309P 2009-03-27 2009-03-27

Publications (1)

Publication Number Publication Date
EA201500552A1 true EA201500552A1 (ru) 2016-07-29

Family

ID=40834101

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201500552A EA201500552A1 (ru) 2008-05-16 2009-05-15 Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью
EA201001771A EA022948B1 (ru) 2008-05-16 2009-05-15 Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201001771A EA022948B1 (ru) 2008-05-16 2009-05-15 Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью

Country Status (30)

Country Link
US (7) US8415301B2 (ru)
EP (2) EP2288373B1 (ru)
JP (4) JP5651586B2 (ru)
CN (3) CN103212063B (ru)
AR (1) AR071810A1 (ru)
AU (1) AU2009246114B2 (ru)
BR (1) BRPI0913011A2 (ru)
CA (1) CA2724540C (ru)
CR (1) CR11749A (ru)
CY (1) CY1116925T1 (ru)
DK (1) DK2288373T3 (ru)
EA (2) EA201500552A1 (ru)
ES (1) ES2546287T3 (ru)
GB (2) GB2459983B (ru)
HK (5) HK1139051A1 (ru)
HR (1) HRP20150845T1 (ru)
HU (1) HUE025483T2 (ru)
IL (3) IL208992A (ru)
MA (1) MA32389B1 (ru)
MX (1) MX2010012450A (ru)
MY (2) MY159803A (ru)
NZ (3) NZ701038A (ru)
PL (1) PL2288373T3 (ru)
PT (1) PT2288373E (ru)
SG (2) SG191587A1 (ru)
SI (1) SI2288373T1 (ru)
TW (1) TWI386202B (ru)
UA (1) UA99953C2 (ru)
WO (1) WO2009140659A2 (ru)
ZA (1) ZA201007449B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2459983B (en) * 2008-05-16 2010-04-28 Corthera Inc Methods of treating dyspnea associated with acute heart failure
CA2724535A1 (en) * 2008-05-16 2009-11-19 Elaine Unemori Use of relaxin to treat chronic heart failure
BR112012022654A2 (pt) * 2010-03-10 2016-11-01 Univ Florida modulação de aquaporinas com relaxina
EP2601532B1 (en) * 2010-08-06 2016-01-27 Mycartis N.V. Perlecan as a biomarker for renal dysfunction
MA34521B1 (fr) 2010-08-17 2013-09-02 Ambrx Inc Polypeptides de relaxine modifiés et leurs utilisations
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
JP2014522641A (ja) * 2011-07-01 2014-09-08 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング リラキシン融合ポリペプチドおよびその使用
WO2013059879A1 (en) * 2011-10-26 2013-05-02 Howard Florey Institute Of Experimental Physiology And Medicine Compositions and methods for the treatment of fibrosis and fibrotic diseases
EP2814513B1 (en) * 2012-02-14 2017-12-20 The Regents of The University of California Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions
ES2929283T3 (es) 2012-05-04 2022-11-28 Us Health Moduladores del receptor de relaxina 1
TR201807636T4 (tr) 2012-10-26 2018-06-21 Chiesi Farm Spa Kalp yetmezliğinde kan basıncının kontrol edilmesi ve dispnenin azaltılması için yöntemler.
AU2014248164B2 (en) 2013-04-05 2019-05-23 Scpharmaceuticals, Inc. Pharmaceutical formulations for subcutaneous administration of furosemide
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN106031247A (zh) * 2014-02-03 2016-10-12 诺华股份有限公司 用于输液装置的过滤器
EP2946788A1 (en) * 2014-05-23 2015-11-25 Immundiagnostik AG Method and composition for treating heart failure with preserved ejection fraction
KR20170018829A (ko) * 2014-06-13 2017-02-20 노파르티스 아게 Gdf-15를 감소시키기 위한 세렐락신의 용도
EP3387019B1 (en) 2015-12-09 2021-10-20 The Scripps Research Institute Relaxin immunoglobulin fusion proteins and methods of use
WO2017139164A1 (en) 2016-02-12 2017-08-17 Cardiac Pacemakers, Inc. Systems and methods for patient monitoring
TW201837051A (zh) 2017-02-08 2018-10-16 美商必治妥美雅史谷比公司 包含藥物動力學增強劑之經修飾之鬆弛素(relaxin)多肽及其用途
US11832970B2 (en) 2017-07-26 2023-12-05 Cardiac Pacemakers, Inc. Worsening heart failure stratification
CN107335051A (zh) * 2017-08-18 2017-11-10 温州医科大学附属第医院 一种保护慢性心衰肾功能的药物组合物
CN113271923A (zh) 2019-01-04 2021-08-17 Sq创新股份公司 呋塞米的药物组合物及其用途
CA3128033A1 (en) 2019-01-31 2020-08-06 Scpharmaceuticals Inc. Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
WO2024047130A1 (en) 2022-08-31 2024-03-07 Relaxera Pharmazeutische Gesellschaft mbH & Co. KG Immunosuppressive medicament and method of treatment

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023321A (en) 1982-12-13 1991-06-11 Howard Florey Institute Of Experimental Physiology & Medicine Molecular cloning and characterization of a further gene sequence coding for human relaxin
US5478807A (en) * 1991-08-19 1995-12-26 Genentech, Inc. Use of relaxin in the treatment of bradycardia
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
DE69432704T2 (de) 1993-06-21 2004-02-26 Genentech, Inc., South San Francisco Verfahren zur Herstellung von humanen Relaxin
WO1995003822A2 (en) 1993-07-27 1995-02-09 Mario Bigazzi Use of relaxin as therapeutic or preventing agent
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
US5811395A (en) 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
WO1997006814A1 (en) 1995-08-15 1997-02-27 Connective Therapeutics, Inc. Method of promoting angiogenesis
AU2001236886A1 (en) 2000-02-09 2001-08-20 Connetics Corporation Use of relaxin to treat diseases related to vasoconstriction
DE10155843A1 (de) * 2000-11-16 2003-01-30 Immundiagnostik Ag Verfahren zur Prognose und Diagnose von Herzinsuffizienz
US20050113286A1 (en) * 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
KR100749857B1 (ko) * 2004-03-30 2007-08-16 연세대학교 산학협력단 릴랙신 유전자를 포함하는 유전자 전달 시스템 및 릴랙신을이용한 약제학적 조성물
US20060264367A1 (en) * 2005-05-21 2006-11-23 Howard Florey Institute Prevention of fibrosis following cardiac injury
US20080077025A1 (en) * 2005-07-11 2008-03-27 Leticia Delgado-Herrera Methods for determining how to treat congestive heart failure
AU2008273813B2 (en) 2007-07-12 2013-06-13 Compugen Ltd. Bioactive peptides and method of using same
CA2724535A1 (en) 2008-05-16 2009-11-19 Elaine Unemori Use of relaxin to treat chronic heart failure
GB2459983B (en) * 2008-05-16 2010-04-28 Corthera Inc Methods of treating dyspnea associated with acute heart failure

Also Published As

Publication number Publication date
JP2015013870A (ja) 2015-01-22
UA99953C2 (ru) 2012-10-25
TW200948353A (en) 2009-12-01
US9066916B2 (en) 2015-06-30
AR071810A1 (es) 2010-07-14
JP5875646B2 (ja) 2016-03-02
ES2546287T3 (es) 2015-09-22
GB0918132D0 (en) 2009-12-02
US8053411B2 (en) 2011-11-08
US20130210730A1 (en) 2013-08-15
CN103212063B (zh) 2015-07-22
US9205132B2 (en) 2015-12-08
HK1151229A1 (en) 2012-01-27
SG10201609580YA (en) 2016-12-29
EP2829280A1 (en) 2015-01-28
CN103212063A (zh) 2013-07-24
US8415301B2 (en) 2013-04-09
AU2009246114A1 (en) 2009-11-19
HK1187550A1 (zh) 2014-04-11
CN102036679A (zh) 2011-04-27
SI2288373T1 (sl) 2015-12-31
GB2459983A (en) 2009-11-18
GB2462221B (en) 2010-09-01
IL247351A0 (en) 2016-09-29
WO2009140659A3 (en) 2010-07-22
IL208992A (en) 2013-09-30
HUE025483T2 (en) 2016-02-29
GB0908432D0 (en) 2009-06-24
HK1202054A1 (en) 2015-09-18
SG191587A1 (en) 2013-07-31
MY159803A (en) 2017-02-15
HRP20150845T1 (hr) 2015-11-06
MX2010012450A (es) 2011-03-21
DK2288373T3 (en) 2015-09-28
JP2011520918A (ja) 2011-07-21
GB2462221A (en) 2010-02-03
CR11749A (es) 2011-02-11
NZ701038A (en) 2016-01-29
US20170151311A1 (en) 2017-06-01
TWI386202B (zh) 2013-02-21
EP2288373A2 (en) 2011-03-02
CN106177914A (zh) 2016-12-07
MA32389B1 (fr) 2011-06-01
NZ589009A (en) 2012-05-25
US20120040902A1 (en) 2012-02-16
US9579363B2 (en) 2017-02-28
CA2724540C (en) 2014-07-08
PL2288373T3 (pl) 2015-11-30
HK1140693A1 (en) 2010-10-22
HK1139051A1 (en) 2010-09-10
WO2009140659A2 (en) 2009-11-19
JP5651586B2 (ja) 2015-01-14
CY1116925T1 (el) 2017-04-05
JP2016053040A (ja) 2016-04-14
ZA201007449B (en) 2011-06-29
EA022948B1 (ru) 2016-03-31
MY158327A (en) 2016-09-30
BRPI0913011A2 (pt) 2019-09-03
GB2459983B (en) 2010-04-28
EA201001771A1 (ru) 2011-06-30
US20120040903A1 (en) 2012-02-16
US20130116181A1 (en) 2013-05-09
US20100048475A1 (en) 2010-02-25
JP5638044B2 (ja) 2014-12-10
US20150320834A1 (en) 2015-11-12
IL228244A (en) 2016-10-31
EP2288373B1 (en) 2015-06-24
JP2013040174A (ja) 2013-02-28
NZ598709A (en) 2013-09-27
CA2724540A1 (en) 2009-11-19
AU2009246114B2 (en) 2013-01-31
IL208992A0 (en) 2011-01-31
US8372809B2 (en) 2013-02-12
PT2288373E (pt) 2015-10-19

Similar Documents

Publication Publication Date Title
EA201500552A1 (ru) Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью
MX336145B (es) Metodo para el tratamiento de insuficiencia cardiaca cronica.
JP2012505014A5 (ru)
WO2011011642A3 (en) Biphasic and dynamic adjustable support devices and methods with assist and recoil capabilities for treatment of cardiac pathologies
MX2010003217A (es) Celulas angiogenicas de perfundido de placenta humana.
PA8794401A1 (es) Acidos 6-fenilnicotinicos sustituidos y su uso
CR20110552A (es) Tratamiento de transtornos resistentes a la insulina
EA201390530A1 (ru) Способ получения сополимера натрийкарбоксиметилцеллюлозы и госсипола и его применение в комплексной терапии пациентов с аутистическими расстройствами и когнитивными нарушениями
UY33453A (es) Método para el tratamiento de la hipertensión pulmonar mediante el uso de ranozalina
MX2011009804A (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo.
MX2010006443A (es) TRATAMIENTO DE CARDIOPATIAS USANDO ß-BLOQUEANTES.
AU2016219717A1 (en) Treating dyspnea associated with acute heart failure with relaxin
WO2013121300A3 (en) Methods for treating psoriasis and vascular inflammation
PH12016500711A1 (en) Method of treating dyspnea associated with acute heart failure
TN2010000504A1 (en) Treating dyspnea associated with acute heart failure with relaxin
AU2013201629B2 (en) Treating dyspnea associated with acute heart failure with relaxin
CU20100225A7 (es) Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina
RU2011148536A (ru) Способ комплексного лечения острой кишечной непроходимости карциноматозного генеза
MD3987B1 (en) Use of Diosmine for the treatment of advancing hepatic cirrhosis associated with cardiac insufficiency
RU2007140029A (ru) Способ лечения хронической сердечной недостаточности
UA69733U (ru) Способ диагностики диастолической дисфункции левого желудочка у больных с неосложненной гипертонической болезнью
UA78607U (ru) Способ оценки эффективности лечения кандесартаном больных ишемической болезнью сердца со стенокардией и артериальной гипертензией с нарушением диастолической функции левого желудочка по "гипертрофическому" типу
UA41944U (ru) Способ прогнозирования выживания больных с хронической сердечной недостаточностью та систолической дисфункцией левого желудочка
UA68459U (ru) Способ оценки эффективности лечения s-метопрололом больных ишемической болезнью сердца со стенокардией и артериальной гипертензией с нарушением диастолической функции левого желудочка по "гипертрофическому" типу
UA107447C2 (ru) Способ оценки эффективности лечения пропранололом больных ишемической болезнью сердца с стенокардией и артериальной гипертензией с нарушением диастолической функции левого желудочка по "гипертрофическому" типу